| Company Name: | CombiMatrix Corporation | | Ticker Symbol: | CBMX | | | WWW Address: | www.combimatrix.com |
| CEO: | Mark D. McDonough | | No. of Employees: | 41 |
| Common Issue Type: | CS | | Business Description: | CombiMatrix Corporation is a molecular diagnostics company that operates mainly in the field of genetic analysis and molecular diagnostics.
|
| | | Industry Information: | HEALTH SERVICES - Medical Laboratories & Research [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 2.92 |  0.41 | 2.86 | 3.05 | 2.89 | 2.85 | 2.65 | 1533408 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 10.5 | 3.6 | 0.23 | -8.75 | 0.00 | 0.0 | 0.0 | 14.14 - 1.40 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 2.70 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 10.5 | mil |
| Latest Shares Outstanding | 3.6 | mil |
| Earnings pS (EPS) | -8.75 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 130,488 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 3.1 | mil |
| Float as % of Shares Outstanding | 99.5 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 132.50 | % |
| Research & Devlopment (R&D) as % of Revenue | 19.90 | % |
| Gross Profit Margin | 57.1 | % |
| EBITDA Margin | -95.3 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.8 | % |
| Return on Assets (ROA) | -112.5 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -317.3 | % |
| Current Ratio | 1.3 | |
| Leverage Ratio (Assets/Equity) | 3.1 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.20 | |
| LT Debt/Total Capital | 8.0 | % |
| Working Capital pS | 0.40 | $ |
| Cash pS | 0.95 | $ |
| Book-Value pS | 0.58 | $ |
| Tangible Book-Value pS | 0.57 | $ |
| Cash Flow pS | -2.18 | $ |
| Free Cash Flow pS | -1.66 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 4.65 | |
| Price/Tangible Book Ratio | 4.76 | |
| Price/Cash Flow | -1.2 | |
| Price/Free Cash Flow | -1.6 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -7.5 | 93 | 1,139 | 3,653 |
| 4 Weeks | 3.44 | 2.65 | 3.32 | -18.7 | 83 | 1,279 | 23,025 |
| 13 Weeks | 4.62 | 2.65 | 3.19 | -15.4 | 81 | 3,715 | 230,352 |
| 26 Weeks | 7.64 | 2.65 | 6.60 | -59.1 | 35 | 5,054 | 621,586 |
| 52 Weeks | 14.14 | 1.40 | 10.00 | -73.0 | 22 | 2,843 | 705,025 |
| YTD | 7.64 | 2.65 | - | -48.9 | 45 | 5,272 | 595,778 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 2.81 | 2.92 | 3.21 | 3.89 | 4.32 | 0.23 | 0.13 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -10.29 | 33.5 | 9.03 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -7.92 | NA | -26.12 |
| R&D | -28.68 | NA | -30.82 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 29.5 | 29.5 | 17.4 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 1.89 | 1.89 | -1.05 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | -27.84 |
| Current Ratio | 0.7 |
| Quick Ratio (Acid Test) | 0.6 |
| Liquidity Ratio (Cash) | 0.42 |
| Receivables Turnover | 3.9 |
| Average Collection Period | 92 |
| Working Capital/Equity | 95.3 |
| Working Capital pS | -0.95 |
| Cash-Flow pS | -6.47 |
| Free Cash-Flow pS | -3.95 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -7.14 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 121.6 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | -69.4 |
| LT Debt/Total Liabilities | 3.6 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | -35.87 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 3.75 |
| Tobin's Q Ratio | 1.87 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -2.15 |
| Enterprise Value (EV)/Free Cash Flow | -2.19 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 4.76 |
| Price/Book Ratio - LTM | 4.65 |
| Price/Cash Flow Ratio | -1.2 |
| Price/Free Cash Flow Ratio - LTM | -1.6 |
| Price/Sales Ratio | 1.70 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.15 |
| Current Liabilities pS | 3.76 |
| Tangible Book Value pS - LTM | 0.57 |
| Book Value pS - LTM | 0.58 |
| Capital Invested pS | -0.25 |
| Cash pS - LTM | 0.95 |
| Cash Flow pS - LTM | -2.18 |
| Free Cash Flow pS - LTM | -1.66 |
| Earnings pS (EPS) | -8.75 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -111.61 |
| Free Cash Flow Margin 5YEAR AVG | -74.94 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | -3.54 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | -5.99 |
| Return on Capital Invested (ROCI) | 1066.9 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -96.7 |
| Assets Productivity | 0.70 |
| Return on Assets (ROA) | -183.9 |
| Return on Assets (ROA) - 5YEAR AVRG. | -71.6 |
| Gross Profit Margin | 57.1 |
| Gross Profit Margin - 5YEAR AVRG. | 51.7 |
| EBITDA Margin - LTM | -95.3 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 153 |
| Revenue per Employee | 130,488 |
| Net Income per Employee | -232,366 |
| Average Collection Period | 85 |
| Receivables Turnover | 3.9 |
| Day's Inventory Turnover Ratio | 68 |
| Inventory Turnover | 5.3 |
| Inventory/Sales | 8.7 |
| Accounts Payble/Sales | 11.40 |
| Assets/Revenue | 1.43 |
| Net Working Capital Turnover | -3.71 |
| Fixed Assets Turnover | 5.67 |
| Total Assets Turnover | 0.7 |
| Revenue per $ Cash | 2.26 |
| Revenue per $ Plant | 8.03 |
| Revenue per $ Common Equity | -3.54 |
| Revenue per $ Capital Invested | -5.99 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 149.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 175.4 |
| Research & Devlopment (R&D) as % of Revenue | 26.2 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 26.2 |
|
|  
|
| |
 |  |
